New Endometriosis Pill Approved for NHS Use in England

A groundbreaking daily pill for endometriosis treatment, relugolix combination therapy, has been approved for NHS use in England and Wales. This marks a significant advancement in managing a condition that affects approximately 1.5 million women in the UK, causing severe pain, fatigue, and fertility issues.

Unlike traditional injectable treatments that require hospital visits, this new oral medication can be taken at home, providing more convenience for patients. The drug works by blocking hormones that contribute to endometriosis while also supplying necessary replacement hormones. It offers a more flexible treatment option, particularly for those planning to have children or managing side effects.

However, access to this treatment is restricted. The National Institute for Health and Care Excellence (NICE) has approved it only for patients who have already attempted all other available medical and surgical options without success—an estimated 1,000 women per year. The cost is £72 for a 28-day supply.

Endometriosis UK welcomes the approval, emphasizing that it offers additional choice but will benefit only a small number of patients. The charity calls for continued research and investment into broader treatment options.

Patients like Ami Clarke, who has endured debilitating symptoms since her teenage years, highlight the urgent need for more accessible and effective treatments. While the new pill represents progress, many still face challenges in diagnosis, treatment accessibility, and symptom management.

This approval signifies a step forward in endometriosis care, allowing some patients greater control over their condition. However, experts stress the importance of ongoing research to develop more inclusive and effective treatments for all those affected.